Elevance Health Inc

Elevance Health maintains a capital structure characterized by significant leverage, with long-term debt of $30.8 billion against total equity of $43.9 billion, resulting in a debt-to-equity ratio of 0.7. The company holds $9.5 billion in cash and equivalents, but net cash is negative after subtracting total debt, indicating a medium liquidity risk profile. The balance sheet shows total assets of $121.5 billion and total liabilities of $77.5 billion. Operating cash flow stands at $4.3 billion, while capital expenditures are $1.1 billion, suggesting adequate cash generation to cover immediate investment needs. Profitability metrics indicate a return on equity of 12.9% and a return on assets of 4.7%. The company reports net income of $5.7 billion on revenue of $199.1 billion, yielding a net margin of approximately 2.8%. Operating income is $7.2 billion, reflecting an operating margin of roughly 3.6%. Without specific cohort median data provided in the input, direct comparative analysis against industry peers is omitted, but the absolute returns suggest stable profitability typical of large-scale health insurers. Segment and geographic revenue mix data is not present in the available input, preventing a detailed analysis of revenue concentration or regional exposure. The company’s activity is broadly defined as Health Care Providers & Services, implying a diversified portfolio of health-related offerings, but specific segment contributions cannot be quantified from the current data set. Growth trajectory analysis is limited due to the absence of historical period data in the input. The latest normalized period shows revenue of $199.1 billion, but year-over-year or multi-year trends cannot be established without prior period figures. Consequently, the sustainability and direction of revenue growth remain unquantified in this assessment. Risk assessment highlights a medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility in adverse scenarios. The dilution risk is rated low, supported by the fact that basic and diluted shares outstanding are identical at 220.7 million, indicating no significant in-the-money options or convertible securities impacting share count. Recent events include a sector contamination re-analysis via the sector classification-direct path, audited on 2026-07-13, which triggered a re-evaluation of the company’s classification. Analyst sentiment is moderately positive, with a mean recommendation of 2.20 (on a 1-5 scale) and a mean price target of $433.37, compared to the current market price of $420.39. The high price target is $498.00, while the low is $331.00, reflecting a wide dispersion in analyst expectations.